Month: September 2026

SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A$856,669 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate was provided in respect of expenditure incurred on eligible R&D activities conducted in the 2025 fiscal year.

This follows approval from AusIndustry of Immutep’s application for an Advance overseas finding. Due to the Advance overseas finding, certain of Immutep’s overseas research and development activities were eligible for the R&D Tax Incentive, in addition to its eligible Australian activities.

Immutep also receives the French CIR tax incentive through its subsidiary Immutep S.A.S. in respect of expenditure incurred on eligible R&D activities conducted in the European Union.

In addition, Immutep is eligible for Germany’s R&D tax incentive program (Forschungszulage) in respect of qualifying internal R&D personnel costs of its German subsidiary, Immutep GmbH. Having received its first payment under this program in Q4 FY26, Immutep may receive further Forschungszulage payments in future years in respect of eligible R&D activities. Any such payments remain subject to the statutory application, assessment and review process, and their amount and timing are uncertain.

Immutep will apply the non-dilutive funding towards furthering its current R&D activities for its product candidates, efti and IMP761. The expected cash reach of the Company extends into the first half of CY2028.

About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the intended use of the R&D tax incentive funding, the Company’s eligibility for and receipt of potential future R&D tax incentive payments, including under Germany’s Forschungszulage, the Company’s expected cash reach, anticipated clinical development, regulatory progress and the potential benefits of efti and IMP761. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, the cost and timing of the Company’s clinical programs, the availability of future funding, and the Company’s ability to advance its product candidates.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

Disclaimer
This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

US Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com

This announcement was authorised for release by the CEO of Immutep Limited.

Company Completes Post-Acquisition Integration and Shared Services Implementation, Reduces Headcount and Third-Party Contractor Spend

SEATTLE, Sept. 30, 2026 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: PARA) (d/b/a “Parabolic” or the “Company”), a leading AI-powered agentic applications technology company, today announced it has completed actions that are expected to result in approximately $9.3 million in annualized cost savings following the integration of ConnectAndSell and implementation of its new business unit operating model.

ConnectAndSell Integration and Cost Synergies

Having completed its post-closing integration of ConnectAndSell, the Company identified opportunities to reduce costs within the business and has taken action to achieve synergies, including a headcount reduction of approximately 12 positions and reduced use of third-party contractors, together representing approximately $3.1 million in estimated annualized savings. These savings are the result of management’s actions to remove duplicate functions and optimize operations, resulting in cost efficiencies that will be fully recognized, on a run rate basis, by the end of FY2026.

New Operating Model and Business Unit Realignment

Under the Company’s new business unit operating model, business unit leaders are now solely focused on customers, service delivery, go-to-market activities, and, ultimately, revenue growth. In connection with this realignment, the Company implemented efficiencies across business units that are expected to result in annualized savings of $6.2 million. The shared services model consolidates administrative functions that are now cost efficient and scalable.

“We are building on the momentum we’ve gained thus far in 2026 and delivering on our cost reduction commitments,” said Joe Davy, Founder and CEO of Parabolic. “Having added substantial revenue via ConnectAndSell, our next objective is absolute financial optimization. These additional cost actions ensure that we convert top-line growth directly into improved operating results and accelerate positive cash generation.”

Financial and Strategic Impact

• ConnectAndSell Integration Synergies: Headcount reduction of 12 positions and reduced third-party contractor spend are expected to contribute $3.1 million in annualized savings. These actions are consistent with the post-closing synergies the Company identified when announcing the acquisition.
• Business Unit Realignment: Operating expense savings of approximately $1.4 million annually by reducing full-time and contractor positions across the Company’s CreateStudio and Banzai business units.
• General and Administrative Cost Reduction: Optimized administrative functions and reduced corporate expenses, contributing an estimated $4.8 million in annualized run-rate savings.
• Total Estimated Annualized Run-Rate Savings: Approximately $9.3 million in combined annualized savings across the initiatives described above.
• Path to Profitability: The Company expects these combined initiatives to meaningfully contribute to its previously stated profitability and cash flow objectives for FY2026 and FY2027.

About Parabolic

Parabolic builds agentic applications that power the future of business. We believe that the future of enterprise software will be agentic applications that are net-beneficiaries of AI transformation, and we focus on building, acquiring, and investing in those and related businesses. We have over 150,000 customers including Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, and Fitch Group. Learn more at www.parabolic.io. For investors, please visit ir.banzai.io.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, statements regarding Banzai International, Inc.’s (the “Company’s”): future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing, future or ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to the Company’s industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for retaining existing or acquiring new customers, increasing revenue and executing growth initiatives; and product areas of focus and additional products that may be sold in the future. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which the Company operates, customer demand, the financial markets, economic, business and regulatory and other factors, such as the Company’s ability to execute on its strategy. More detailed information about risk factors can be found in the Company’s Annual Report on Form 10-K and the Company’s Quarterly Reports on Form 10-Q under the heading “Risk Factors,” and in other reports filed by the Company, including reports on Form 8-K. The Company does not undertake any duty to update forward-looking statements after the date of this press release.

Investor Relations
Dean Ditto
Chief Financial Officer
206 414-1777
ir.banzai.io

Media
Paul Witkowski
Senior Director Financial Reporting
media@banzai.io

TOKYO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Tokyo Lifestyle Co., Ltd. (“Tokyo Lifestyle” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in Hong Kong, Japan, North America, Thailand, Vietnam, the United Kingdom and Australia, today highlighted its commitment to shareholder returns following the payment of a year-end cash dividend of JPY1.890 per share for the fiscal year ended March 31, 2026.

At the Company’s 20th annual general meeting of shareholders held on June 26, 2026, shareholders approved the proposed cash dividend, which was payable during the period from September 14 through September 30, 2026, to shareholders of record as of March 31, 2026. As of September 30, 2026, the dividend had been paid in full to all eligible shareholders.

The Company believes the dividend reflects its ongoing focus on returning value to shareholders while maintaining a disciplined approach to capital allocation and financial management. While continuing to pursue its business development initiatives, the Company remains focused on balancing the capital requirements of its operations and long-term growth strategy with its commitment to shareholder returns.

Tokyo Lifestyle believes that maintaining this balance is important to preserving financial flexibility and supporting sustainable long-term development and value creation. Going forward, the Company intends to continue evaluating capital allocation priorities in light of its business needs, financial position and long-term objectives, with a focus on supporting business growth while creating sustainable value for shareholders.

Mr. Mei Kanayama, Principal Executive Officer of Tokyo Lifestyle, commented: “We greatly appreciate the continued strong trust and support of our shareholders. The year-end cash dividend reflects our confidence in the Company’s continued development and our commitment to sharing the benefits of that progress with our shareholders.

“Looking ahead, we will remain focused on executing our business strategy, strengthening our operations and pursuing opportunities for sustainable growth across our markets. At the same time, we will continue to manage our capital prudently, allocating resources in a disciplined manner to support both our near-term operating needs and longer-term growth initiatives. We believe this approach will enable us to maintain a strong financial foundation while creating lasting value for our shareholders.”

About Tokyo Lifestyle Co., Ltd.

Headquartered in Tokyo, Japan, Tokyo Lifestyle Co., Ltd. (formerly known as Yoshitsu Co., Ltd) is a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys, and other products in Hong Kong, Japan, North America, Thailand, Vietnam, the United Kingdom and Australia. The Company offers various beauty products (including cosmetics, skincare, fragrance, and body care products), health products (including over-the-counter drugs, nutritional supplements, and medical supplies and devices), sundry products (including home goods), collectible cards and trendy toys (including Pokémon cards, BE@RBRICK and other trendy products) and other products (including food and alcoholic beverages). The Company currently sells its products through directly-operated physical stores, through online stores, and to franchise stores and wholesale customers. For more information, please visit the Company’s website at https://www.ystbek.co.jp/irlibrary/.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s annual report and in its other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

Tokyo Lifestyle Co., Ltd.
Investor Relations Department
Email: ir@ystbek.co.jp

Ascent Investor Relations LLC
Tina Xiao
President
Phone: 1-646-932-7242
Email: investors@ascent-ir.com

San Diego, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — California BanCorp (the “Company”) (Nasdaq: BCAL), the holding company for California Bank of Commerce, N.A. (the “Bank”), announces that the Bank plans to open a new commercial loan production office at 595 Market Street in downtown San Francisco on October 1, 2026. The new office reflects the Bank’s continued commitment to strategic growth and will expand its commercial banking presence in the Bay Area.

“Establishing a physical presence in San Francisco allows the Bank to better serve the city’s diverse and innovative business community. This new office broadens our reach in Northern California and advances our mission to provide responsive, locally focused commercial banking services to privately held businesses,” said David Rainer, Chairman and CEO of the Company and Bank.

ABOUT CALIFORNIA BANCORP

California BanCorp (NASDAQ: BCAL) is a registered bank holding company headquartered in San Diego, California. California Bank of Commerce, N.A., a national banking association chartered under the laws of the United States (the “Bank”) and regulated by the Office of Comptroller of the Currency, is a wholly owned subsidiary of California BanCorp. Established in 2001 and headquartered in San Diego, California, the Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving California. The Bank’s solutions-driven, relationship-based approach to banking provides accessibility to decision makers and enhances value through strong partnerships with its clients. Additional information is available at www.californiabankofcommerce.com.

INVESTOR RELATIONS CONTACT
ir@bankcbc.com

PLANO, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading global medical device contract development and manufacturing organization (CDMO), today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with the previously announced acquisition of Integer by an affiliate of investment funds managed by KKR (the “Merger”).

As previously announced on August 3, 2026, Integer and KKR entered into a definitive merger agreement dated as of August 2, 2026 (the “Merger Agreement”) pursuant to which an affiliate of KKR will acquire all of the outstanding shares of Integer for $127 per share in cash (the “Transaction”). The Transaction represents a total enterprise value of approximately $5.7 billion. The termination of the HSR waiting period satisfies one of the conditions required for completion of the Transaction. The Transaction remains subject to approval of Integer stockholders and the satisfaction or waiver of other regulatory approvals and other customary closing conditions. Integer continues to expect the Transaction to close by the end of 2026, subject to the satisfaction of these conditions.

Integer will hold a virtual Special Meeting of Stockholders (the “Special Meeting”) on October 21, 2026 at 9:00 a.m., Central Time, to vote to adopt the Merger Agreement, and approve other related proposals. Stockholders of record as of the close of business on September 8, 2026, are entitled to vote at the meeting. The Integer Board of Directors unanimously recommends that all Integer stockholders vote “FOR” the Merger Agreement and other related proposals.

For more information about the proposed Transaction, including the Merger Agreement, the Merger, and the Special Meeting, please see the definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) by Integer on September 14, 2026 (the “Definitive Proxy Statement”).

About Integer^®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The Company’s brands include Greatbatch Medical^® and Lake Region Medical^®. Additional information is available at www.integer.net.

Contacts
Integer
Media Relations:
Misty Tippen
misty.tippen@integer.net
469-536-6702

Investor Relations:
Kristen Stewart
kristen.stewart@integer.net
551-337-3973

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements contained in this communication and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include, but are not limited to, statements relating to: our goals, plans, and strategic initiatives; long-term growth prospects; maximizing value for our stockholders; and other events, conditions or developments that will or may occur in the future; and timing of any of the foregoing. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,” “assume,” “potential” or “continue” or variations or the negative counterparts of these terms or other comparable terminology. These statements are only predictions and are no guarantee of future performance, and investors should not place undue reliance on forward-looking statements as predictive of future results. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this communication.

Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements regarding the transactions contemplated by the Agreement and Plan of Merger, by and among the Company, Armstrong Parent, Inc. (“Buyer”) and Armstrong Bidco, Inc. All such forward-looking statements are based upon current plans, estimates, expectations, opportunities and ambitions that are subject to risks, uncertainties, assumptions, and other important factors, many of which are beyond the control of the Company, that could cause actual results to differ materially from those expressed in such forward-looking statements. Key factors that could cause actual results to differ materially include, but are not limited to, the expected timing and likelihood of completion of the Transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals; the occurrence of any event, change or other circumstances that could give rise to the termination of the Transaction; the possibility that the Company’s stockholders may not approve the Transaction; the risk that the parties may not be able to satisfy the conditions to the Transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the Transaction; the risk that any announcements relating to the Transaction could have adverse effects on the market price of the Company’s common stock; the risk that the Transaction and its announcement could have an adverse effect on the parties’ business relationships and business generally, including the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers, and on their operating results and businesses generally; the risk of unforeseen or unknown liabilities; customer, stockholder, regulatory and other stakeholder approvals and support; the risk of unexpected future capital expenditures; the risk of potential litigation relating to the Transaction that could be instituted against the Company or its directors and/or officers; the risk associated with third-party contracts containing material consent, anti-assignment, transfer or other provisions that may be related to the Transaction which are not waived or otherwise satisfactorily resolved; significant costs, or expenses incurred in connection with the Transaction; the Buyer’s ability to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the Transaction; certain restrictions contained in the Agreement and Plan of Merger that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; the risk of various events that could disrupt operations, including pandemics, epidemics or other public health crises or severe weather (such as droughts, floods, avalanches and earthquakes), cybersecurity attacks, security threats and governmental response to them, and technological changes; the risks of labor disputes, changes in labor costs and labor difficulties; and the risks resulting from other effects of industry, market, economic, legal or legislative, political or regulatory conditions outside of the Company’s control. All such factors are difficult to predict and are beyond our control, including those detailed in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on February 23, 2026, the Company’s quarterly report on Form 10-Q for the fiscal quarter ended July 3, 2026, which was filed with the SEC on August 4, 2026 and other documents subsequently filed by the Company with the SEC. The Company’s forward-looking statements are based on assumptions that the Company believes to be reasonable but that may not prove to be accurate. Other unpredictable factors not discussed in this communication could also have material adverse effects on forward-looking statements. The Company does not assume an obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements speak only as of the date hereof.

Additional Information and Where to Find It

In connection with the Transaction, the Company filed the Definitive Proxy Statement with the SEC on September 14, 2026. The Definitive Proxy Statement and proxy card have been mailed to Integer’s stockholders of record as of the close of business on September 8, 2026. The Definitive Proxy Statement seeks their approval of the Transaction and other related matters. INTEGER’S STOCKHOLDERS AND INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY CONTAIN, OR WILL CONTAIN, IMPORTANT INFORMATION ABOUT THE TRANSACTION AND RELATED MATTERS.

Investors and security holders may obtain free copies of these documents, including the proxy statement, and other documents filed with the SEC by the Company through the website maintained by the SEC at https://www.sec.gov. Copies of documents filed with the SEC by the Company will be made available free of charge by accessing the Company’s website at https://investor.integer.net/financial-information/sec-filings/default.aspx or by contacting the Company via email by sending a message to ir@integer.net.

Participants in the Solicitation

The Company, Buyer and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the Transaction under the rules of the SEC. Information about the directors and executive officers of the Company and other persons who may be deemed to be participants in the solicitation of stockholders of the Company in connection with the Transaction and a description of their direct and indirect interests, by security holdings or otherwise, is included in the “The Merger (PROPOSAL 1) – Interests of ITGR’s Directors and Executive Officers in the Merger” and the “Security Ownership of Certain Beneficial Owners and Management” sections of the Definitive Proxy Statement. The Definitive Proxy Statement and other documents may be obtained free of charge from the SEC’s website at www.sec.gov.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or the solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

MCLEAN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU), a leading provider of cybersecurity, information technology, and public safety solutions, today announced that Chairman and Chief Executive Officer L. Kevin Kelly participated in a featured interview with SmallCapVoice.com, Inc., where he discussed the Company’s recent operational milestones, including its largest contract award to date, the acquisition of Digital Ally’s Video Solutions business, expansion within the public safety sector, and Cycurion’s long-term growth strategy.

During the interview, Kelly highlighted Cycurion’s previously announced $54.6 million, 10-year contract award, the largest in the Company’s history, secured through a leading global consulting firm. The contract supports the modernization and secure operation of a major state Health and Human Services system and is expected to generate more than $5 million in annual revenue, with work scheduled to commence in November 2026.

Kelly noted that this landmark award underscores Cycurion’s growing industry reputation, deep cybersecurity expertise, and long-standing client relationships, further validating the Company’s ability to deliver mission-critical security solutions at scale.

The full interview is available here: https://youtu.be/wZBAElMDjF8

“We believe this contract validates both the quality of our people and the evolution of Cycurion’s strategic positioning in the market,” said Kelly. “As we continue moving toward larger, higher-value opportunities, we are seeing increased demand for our specialized cyber capabilities and a growing recognition of the value we bring to major enterprises and government engagements.”

Kelly also discussed Cycurion’s acquisition of Digital Ally’s Video Solutions business, which adds an established public safety technology portfolio, approximately $5.5 million in annual revenue, more than $1.2 million in EBITDA, an installed customer base of over 800 law enforcement agencies, and a portfolio of intellectual property assets. Upon the closing, Cycurion’s pro forma gross revenue run rate stands at approximately $30 million.

“The Digital Ally acquisition is an important step in expanding our public safety ecosystem,” Kelly said. “The transaction adds recurring revenue, attractive margins, valuable technology assets, and significant cross-selling opportunities. By combining advanced public safety technologies with Cycurion’s cybersecurity expertise, we believe we can deliver differentiated solutions that address the evolving needs of law enforcement, emergency services, transportation, and critical infrastructure clients.”

The interview also explored Cycurion’s expanding public safety footprint, including recent municipal and state-level engagements. According to Kelly, public safety continues to serve as a strategic foundation for the Company’s broader expansion into federal government and commercial cybersecurity markets.

“Public safety remains a critical growth area for Cycurion,” Kelly added. “These engagements provide long-term relationships, recurring revenue opportunities, and a platform to introduce additional cybersecurity and technology solutions. At the same time, we are continuing to pursue larger federal opportunities while building new commercial offerings designed to accelerate growth and improve margins.”

Kelly further discussed Cycurion’s strategic vision, including plans to expand its offensive cybersecurity capabilities through new technologies designed to identify vulnerabilities before organizations are breached.

“As cyber threats continue to evolve, organizations are looking beyond traditional defensive solutions,” Kelly said. “We are investing in next-generation capabilities that help customers identify and address vulnerabilities proactively. We believe this approach positions Cycurion to capitalize on emerging opportunities across both government and commercial sectors.”

Looking ahead, Kelly reiterated management’s focus on profitable growth, operational execution, and increasing shareholder value.

“We have made significant progress strengthening the Company’s financial foundation, reducing debt, improving margins, securing long-term contract visibility, and expanding our technology portfolio,” Kelly concluded. “Our team remains focused on execution, and we believe the initiatives currently underway position Cycurion for continued growth as we work toward our long-term objectives.”

About Cycurion

Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of AI-enabled IT cybersecurity solutions, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future. For more information, visit www.cycurion.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Such statements include, but are not limited to, the expected revenue, EBITDA and other anticipated financial and operational benefits arising from the acquisition of the Digital Ally video solutions business (the “Business”); statements regarding the anticipated commercial benefits of the Company’s patents, including expected expansion of the Company’s customer base and expected effects on customer retention; statements regarding the scope, validity, enforceability, and remaining term of the Company’s issued patents; statements regarding the availability of the patented functionality across the Company’s installed base of deployed systems; statements regarding the number of client relationships acquired in the Business; statements regarding the Company’s pro forma gross revenue run rate; statements regarding the Company’s execution of its strategic plan; the anticipated benefits, timing, and integration of pending or completed acquisitions; the performance of and revenue expected from government and commercial contracts; the development and commercialization of the Company’s AI-enabled cybersecurity platforms, including ARx; the Company’s expectations regarding its path to profitability; the Company’s ability to regain or maintain compliance with the continued listing standards of the Nasdaq Stock Market; and the conduct, timing, and outcome of the Company’s investigations and any related legal proceedings. Forward-looking statements may be accompanied by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” and similar expressions.

Forward-looking statements are based on management’s current expectations and assumptions and involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied, many of which are outside the Company’s control and difficult to predict. These risks include, but are not limited to: the Company’s ability to develop, market, and sell products incorporating the patented technology; the possibility that the patented technology does not increase customer retention or expand the Company’s customer base as anticipated; the outcome of the Company’s investigations and any legal proceedings the Company may initiate or become subject to, and the costs, time, and resources associated with such matters; the Company’s ability to identify, finance, complete, and integrate acquisitions; risks relating to the Company’s intellectual property, including that issued patents may be challenged, narrowed, invalidated, or designed around, that they may not provide meaningful competitive advantage or barriers to entry, and that third parties may assert infringement claims against the Company; the Company’s ability to win, retain, and perform under government and commercial contracts; the Company’s need for additional capital and the terms on which it may be available; the Company’s ability to satisfy Nasdaq’s continued listing requirements; competitive conditions and technological change in the cybersecurity market; and volatility in the trading price and volume of the Company’s common stock, which may occur for reasons unrelated to the Company’s operating performance. Additional risks and uncertainties are described in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

Forward-looking statements speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to update any forward-looking statement.

Cycurion Investor Relations:
(888) 341-6680
investors@cycurion.com

Cycurion Media Relations:
(888) 341-6680
media@cycurion.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/566c30d8-ff54-4476-8120-00364fd810bc

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/5ed1a647-4348-478a-a5a5-04c9acfefe74

– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –

WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on a new analysis of Phase 3 trials of YCANTH® (VP-102) and an encore presentation of data from a Phase 2 trial of VP-315. Verrica will present at the Fall Clinical Dermatology Conference (October 8–11, Wynn Las Vegas, Las Vegas, NV) and at the 2026 PeDRA Annual Conference (October 15–17, Alexandria, VA).

“We remain highly encouraged by the continued generation of clinical evidence supporting our dermatology portfolio,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “These new pooled data from the CAMP-1 and CAMP-2 Phase 3 trials reinforce VP-102’s profile as the new standard of care for molluscum contagiosum, showing that patients may achieve complete clearance of their molluscum lesions approximately four times faster than with vehicle, regardless of how long patients have had the disease. In addition, three times as many patients treated with YCANTH achieved complete clearance versus vehicle at each time point measured during the two trials, which reflects the consistent and durable treatment effects of YCANTH. We believe this new analysis provides physicians further confidence to treat patients with YCANTH as soon as a diagnosis is made, rather than defaulting to a ‘watch and wait’ approach typically employed by healthcare professionals before an FDA-approved option existed for patients.”

“We continue to analyze the YCANTH data to help us better understand its ability to reduce the impact of disease upon patients, and accelerate their return to normal activities,” added Noah L. Rosenberg, M.D., Chief Medical Officer of Verrica. “This data, demonstrating more rapid complete clearance with YCANTH, independent of disease duration, gives clinicians a clear, data-driven rationale for early intervention rather than watchful waiting.”

About the Posters:

VP-102 Achieved Complete Clearance Approximately 4 Times Faster Than Vehicle, Regardless of Disease Duration

The Company will present results from a post-hoc pooled analysis of two completed Phase 3 trials of YCANTH for the treatment of molluscum contagiosum (molluscum), evaluating time to first complete clearance and the impact of disease duration on treatment response.

Key new findings include:

• Subjects treated with VP-102 achieved complete clearance at an approximately 4-fold faster rate than vehicle (HR=4.06; 95% CI, 2.94–5.74), with treatment-effect estimates ranging from 4.05 to 4.19 across sensitivity analyses.
• Kaplan-Meier cumulative complete clearance by Day 84 was 60.1% with VP-102 versus 19.9% with vehicle.

Potential Abscopal Effect of VP-315 in Untreated Basal Cell Carcinoma Tumors

Verrica will present an encore poster, previously presented at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, describing an exploratory analysis of potential abscopal-like effects of VP-315, the Company’s investigational oncolytic peptide immunotherapy, in patients with basal cell carcinoma (BCC). The analysis examined untreated, non-target lesions (NTLs) in subjects from Part 2 of a Phase 2 multicenter study following intratumoral treatment with VP-315 of separate target lesions.

Presentation Details

2026 Fall Clinical Dermatology Conference | October 8–11, 2026 | Wynn Las Vegas, Las Vegas, NV

• Poster: VP-102 Demonstrates More Rapid Complete Clearance of Molluscum Contagiosum Regardless of Disease Duration: A Pooled Analysis of Two Phase 3 Trials
  Convention/Meeting Space: Cristal Ballrooms 1, 3, 5, 7
  Time of Poster Session:
  • Friday, October 9^th, 7:00 am – 6:00 pm PDT with Scientific Poster Review session from 4:00 pm -5:00 pm PDT
  • Saturday, October 10^th, 7:30 am – 12:30 pm PDT (Exhibits and Poster Gallery Open)
  • Sunday, October 11^th, 7:00 am – 1:00 pm PDT (Poster Gallery Open)

• Poster: VP-315 Demonstrates a Potential Abscopal Effect in Untreated Non-Target Basal Cell Carcinoma (BCC) Tumors (Encore)
  Convention/Meeting Space: Cristal Ballrooms 1, 3, 5, 7
  Time of Poster Session:
  • Friday, October 9^th, 7:00 am – 6:00 pm PDT with Scientific Poster Review session from 4:00 pm -5:00 pm PDT
  • Saturday, October 10^th, 7:30 am – 12:30 pm PDT (Exhibits and Poster Gallery Open)
  • Sunday, October 11^th, 7:00 am – 1:00 pm PDT (Poster Gallery Open)

2026 PeDRA Annual Conference | October 15–17, 2026 | Alexandria, VA

• Poster: VP-102 Demonstrates More Rapid Complete Clearance of Molluscum Contagiosum Regardless of Disease Duration: A Pooled Analysis of Two Phase 3 Trials
  Convention/Meeting Space: Hilton Alexandria Mark Center
  Time of Poster Session: October 15-17, 2026 (Poster Reception Thursday, October 15^th at 5:00 pm EDT)

About YCANTH® (VP-102)

YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Please visit YCANTHPro.com for additional information.

YCANTH is now approved for the treatment of molluscum contagiosum in Japan based upon an additional Phase 3 trial of approximately 300 patients. YCANTH is being studied in a global Phase 3 program in the US and Japan for use in the treatment of common warts.

About VP-315 (ruxotemitide)

VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death and thereby unleashing a broad spectrum of tumor antigens for T cell responses, which may offer a non-surgical option for patients suffering from skin cancer. The technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Verrica holds an exclusive worldwide license to develop and commercialize VP-315 for certain dermatologic oncology indications, including non-metastatic melanoma and non-metastatic merkel cell carcinoma, and intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development. VP-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials.

About Verrica Pharmaceuticals Inc.

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315, and the data described in this press release. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Reports on Form 10-Q and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John Kirby
Interim Chief Financial Officer
jkirby@verrica.com

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the Company’s common stock, Series A warrants to purchase up to an aggregate of 735,296 shares of common stock and Series B warrants to purchase up to an aggregate of 735,296 shares of common stock, at a purchase price of $4.08 per share and associated warrants in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.83 per share and will be exercisable immediately upon issuance. The Series A warrants will expire five years after the effective date of the Resale Registration Statement (as defined below) and the Series B warrants will expire twenty-four months after the effective date of the Resale Registration Statement.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering are expected to be approximately $3 million, before deducting placement agent fees and other offering expenses. If the Series A and Series B warrants are exercised in full for cash, the Company would receive additional gross proceeds of approximately $5.6 million. There can be no assurance that any of the warrants will be exercised. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants sold in the offering, have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock to be issued in the offering and issuable upon exercise of the warrants to be issued in the offering (the “Resale Registration Statement”).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BioStem Technologies, Inc. (Nasdaq: BSEM):

BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.

Forward-Looking Statements:

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this press release include, without limitation, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the potential exercise of the warrants and the intended use of net proceeds from the offering.

Forward-looking statements with respect to strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; the Company’s ability to obtain financing on terms acceptable to it, or at all; the impact of any changes in applicable laws or regulations; the Company’s accounts receivable collection risk and concentration; the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and the possibility that the Company may be adversely affected by other general economic, business, and/or competitive factors. There may be additional risks about which the Company is presently unaware of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company undertakes no duty to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin Group
ir@biostemtech.com

SINGAPORE, Sept. 30, 2026 (GLOBE NEWSWIRE) — HomesToLife Ltd (Nasdaq: HTLM) (“HomesToLife” or the “Company”), a Singapore-based home furniture company with sales across Asia-Pacific, Europe and North America, today announced its unaudited financial results for the six months ended June 30, 2026 (“1H 2026”).

Key Financial Highlights
		1H 2025 US$’000			1H 2026 US$’000			Change
Net revenue		180,775			198,305			10	%
Retail		3,382			5,314			57	%
Export		168,009			186,293			11	%
Leather Trading		9,383			6,698			(29	%)
By geographical		180,775			198,305			10	%
Asia Pacific		48,683			46,680			(4	%)
Europe		109,989			123,660			12	%
North America		22,103			27,966			27	%
Gross profit		49,833			56,994			14	%
Gross profit margin		27.6	%		28.7	%		1.1	pp
Operating expenses		(40,784	)		(47,295	)		16	%
Sales and distribution expenses		(31,092	)		(36,967	)		19	%
General and Administrative expenses		(9,692	)		(10,328	)		7	%
Income from operations		9,048			9,698			7	%
Net income		10,024			6,068			(39	%)
Earnings per share (Basic and diluted)		0.11			0.07			(39	%)

Financial results for the six months ended June 30, 2025 (“1H 2025”) and 1H 2026, unless otherwise stated, reflect the inclusion of HTL Marketing Pte. Ltd. (“HTL Marketing”) because of the acquisition of 100% of equity interests in HTL Marketing completed on May 19, 2025.

1H 2026 Performance

In 1H 2026, the Company delivered strong net revenue of US$198.3 million, representing a year-on-year increase of 10%, driven by a US$18.3 million increase in export sales. By region, net revenue from North American and Europe markets saw 27% and 12% growth respectively compared to 1H 2025, while Asia Pacific market experienced a slight decline by 4%. Retail sales continued to support the revenue growth with a 57% year-on-year increase, attributable to the expansion of the retail stores and retail sales growth in South Korea.

Gross profit rose 14% from US$49.8 million in 1H 2025 to US$57.0 million in 1H 2026, with margins expanding by 1.1 percentage points. The continuous growth was primarily attributable to a favorable shift in sales mix, along with the better sales performance in both Europe and North America. Operating expenses increased by US$6.5 million due to higher selling expenses along with larger sales volumes and increased freight and logistics costs.

Income from operations reached US$9.7 million in 1H 2026, rising by 7% from US$9.0 million in 1H 2025. In the meantime, net income decreased from US$10.0 million in 1H 2025 to US$6.1 million in 1H 2026, primarily resulting from a net foreign exchange loss of US$2.2 million during the reporting period, compared with a foreign exchange gain of US$4.3 million in the same period last year. Excluding foreign exchange gain (loss), net income would have increased by 22% from US$6.5 million in 1H 2025 to US$7.9 million in 1H 2026. Earnings per share stood at US$0.07 in 1H 2026.

Financial Position

Cash outflows from operating activities improved with a reduction from US$11.3 million in 1H 2025 to US$8.3 million in 1H 2026, representing a year-on-year decrease of 26%. Net cash used in investing activities amounted to US$2.0 million, and net cash provided by financing activities amounted to US$1.5 million during the reporting period.

As of June 30, 2026, the Company maintained a healthy liquidity position, as cash and cash equivalents totalled US$17.9 million after US$5.8 million dividend payments and short-term borrowings reduced to US$7.3 million as of June 30, 2026 from US$10.4 million as of December 31, 2025. Net current assets were US$18.3 million, underscoring the Company’s positive working capital profile.

Outlook

HomesToLife expects to maintain stable sales growth for the remainder of FY2026, in line with its earlier guidance of US$400 million to US$420 million for the full year. Building on its growing export business and diversified revenue base, the Company will remain focused on enhancing operational efficiency, prudent cost management, and working capital optimization to support sustainable long-term growth.

The Company will also continue to closely monitor external factors that may affect operating performance, including foreign exchange movements, logistics costs, raw material prices, and broader macroeconomic as well as geopolitical developments. While foreign exchange movements affected reported net income during the reporting period, the Company continues to actively manage its foreign-exchange exposure through natural hedges and risk-management measures while maintaining its geographically diversified operations, helping to mitigate the impact of currency volatility and support resilient business performance.

“The first half of 2026 demonstrated the strength of our business fundamentals and the benefits of our diversified global strategy,” said Ms. Phua Mei Ming, Chief Executive Officer of HomesToLife. “While we remain mindful of ongoing market uncertainties, we are optimistic about the opportunities ahead. We will continue to proactively manage risks, invest in product innovation, and strengthen our presence across key markets.”

The Company remains in progress with its proposed secondary listing (“Proposed Secondary Listing”) on the Main Board of the Singapore Exchange Securities Trading Limited (the “SGX-ST”). The Proposed Secondary Listing remains subject to regulatory review and approval, and if approved, the fulfilment of certain conditions and other applicable listing requirements.

About HomesToLife Ltd (Nasdaq: HTLM)

HomesToLife Ltd is a global furniture company headquartered in Singapore. Leveraging 50 years of heritage built by its founders, the Company combines wholesale distribution, consumer retail, and sourcing capabilities, supported by a diversified sourcing and supplier network across China, Vietnam and India.

The Company operates through three core business divisions: (i) export division for supplying furniture to wholesale customers such as retailers and distributors worldwide, (ii) leather trading division and (iii) retail division with direct retail operations in Singapore and South Korea.

Across these business divisions, the Company operates an integrated supply chain model that encompasses product design and development, sourcing from the Company’s manufacturing partners, and the coordination of logistics and distribution channels. This operating model enables the Company to translate designs into production-ready products efficiently, supporting both branded and white-label offerings, and allows the Company to deliver scale and consistency across multiple markets.

The Company is fast expanding across Europe, Asia-Pacific, and North America, leveraging an integrated supply chain model and a global presence to deliver scale and consistency across multiple markets.

FORWARD-LOOKING STATEMENTS

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

CAUTIONARY STATEMENT

The Proposed Secondary Listing remains subject to regulatory review and approval, and if approved, the fulfilment of certain conditions and other applicable listing requirements. As such, there is no assurance that the Proposed Secondary Listing will proceed to completion. The Company will provide further updates as and when there are material developments, in accordance with applicable laws and regulatory requirements.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares and to refrain from taking any action in respect of their shares which may be prejudicial to their interests. Shareholders and potential investors who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor, accountant, tax adviser or other professional adviser.

Contacts

HomesToLife Ltd Contact:

12 Tai Seng Link, #03-01A,
GRC Centre, Singapore 534233
Email: Investor@homestolife.com

Investor Relations Inquiries:

Edelman Smithfield
Angela Hui
HomesToLife@edelmansmithfield.com

HOMESTOLIFE LTD AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Currency expressed in United States Dollars (“US$”), except for number of shares)
		As of
		December 31, 2025				June 30, 2026
ASSETS
Current assets:
Cash and cash equivalents		$	27,276,091			$	17,941,401
Restricted Cash			–				164,026
Accounts receivables, net (including receivable from related parties of $5,763,509 and nil as of December 31, 2025 and June 30, 2026, respectively)			76,010,709				74,811,081
Inventories, net			9,599,490				10,120,517
Amounts due from related parties			7,026,092				–
Deposit, prepayments and other receivables			5,853,470				6,741,958
Total current assets			125,765,852				109,778,983
Non-current assets:
Property, plant and equipment, net			4,354,206				5,884,250
Right-of-use assets, net			7,363,312				7,528,176
Restricted cash, non-current			–				111,136
Investments in equity securities			–				1,000,000
Other non-current assets			1,000,000				–
Deferred tax asset, net			673,416				689,142
Total non-current assets			13,390,934				15,212,704
TOTAL ASSETS		$	139,156,786			$	124,991,687
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	4,475,242			$	4,587,814
Accounts payable, related parties			74,890,989				63,749,207
Customer deposits			1,195,989				1,188,847
Accrued liabilities and other payables			6,065,126				6,697,637
Short-term borrowings			10,389,094				7,263,986
Lease liabilities, current			1,924,657				2,299,696
Warranty liabilities			2,188,814				1,930,960
Derivatives financial instruments			74,765				–
Income tax payable			4,156,085				3,718,772
Total current liabilities			105,360,761				91,436,919
Long-term liabilities:
Provision for reinstatement cost			382,112				502,676
Lease liabilities			5,572,603				5,377,461
Total long-term liabilities			5,954,715				5,880,137
TOTAL LIABILITIES			111,315,476				97,317,056
Commitments and contingencies			–				–
Shareholders’ equity:
Ordinary share, $0.0001 par value, 500,000,000 shares authorized,89,687,500 and 89,687,500 shares issued and outstanding as of December 31, 2025 and June 30, 2026, respectively			8,969				8,969
Additional paid-in capital			37,179,424				37,179,424
Accumulated other comprehensive loss			(12,111,193	)			(12,515,722	)
Retained earnings			2,764,110				3,001,960
Total shareholders’ equity			27,841,310				27,674,631
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$	139,156,786			$	124,991,687

HOMESTOLIFE LTD AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Currency expressed in United States Dollars (“US$”), except for number of shares)
		Six months ended June 30
		2025				2026
Revenues, net
From third parties		$	170,117,861			$	190,732,226
From related parties			10,656,942				7,572,880
			180,774,803				198,305,106
Cost of goods sold			(130,942,258	)			(141,311,428	)
Gross profit			49,832,545				56,993,678
Operating expenses:
Sales and distribution expenses			(31,092,110	)			(36,967,422	)
General and administrative expenses			(9,691,952	)			(10,327,858	)
Total operating expenses			(40,784,062	)			(47,295,280	)
Income from operations			9,048,483				9,698,398
Other income (expense):
Interest expense			(730,372	)			(150,615	)
Interest income			16,246				19,193
Government subsidies			16,950				23,385
Foreign exchange gain (loss), net			4,293,633				(2,168,357	)
Net gain from related parties debt restructuring			1,460,543				–
Professional fees on acquisition of HTL Marketing			(1,261,560	)			–
Scrap sofa sale income			223,263				165,621
Change in fair value of derivatives financial instruments			(753,243	)			74,765
Sundry income(expense)			39,404				148,095
Total other income (expense), net			3,304,864				(1,887,913	)
Income before income taxes			12,353,347				7,810,485
Income tax expense			(2,329,272	)			(1,742,947	)
NET INCOME		$	10,024,075			$	6,067,538
Other comprehensive income (loss):
– Foreign currency translation adjustments			1,368,175				(404,529	)
COMPREHENSIVE INCOME		$	11,392,250			$	5,663,009
Weighted average number of ordinary shares:
Basic and diluted			89,687,500				89,687,500
EARNINGS PER SHARE – BASIC AND DILUTED		$	0.11			$	0.07

HOMESTOLIFE LTD AND SUBSIDIARIES
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Currency expressed in United States Dollars (“US$”), except for number of shares)
		Six months ended June 30, 2025
		Retail Sales				Export Sales				Leather Trading				Corporate and unallocated				Total
Revenues, net
From third party		$	3,382,273			$	166,459,189			$	276,399			$	–			$	170,117,861
From related parties			–				1,550,023				9,106,919				–				10,656,942
			3,382,273				168,009,212				9,383,318				–				180,774,803
Cost of goods sold			(1,401,494	)			(120,526,294	)			(9,014,470	)			–				(130,942,258	)
Gross profit			1,980,779				47,482,918				368,848				–				49,832,545
Operating expenses:
Sales and distribution expenses			(2,404,689	)			(28,634,760	)			(52,661	)			–				(31,092,110	)
General and administrative expenses			(906,968	)			(8,099,908	)			(3,025	)			(682,051	)			(9,691,952	)
Total operating expenses			(3,311,657	)			(36,734,668	)			(55,686	)			(682,051	)			(40,784,062	)
Operating income (loss)			(1,330,878	)			10,748,250				313,162				(682,051	)			9,048,483
Other income (expenses):
Interest expense			(125,183	)			(394,423	)			(210,766	)			–				(730,372	)
Interest income			130				15,946				170				–				16,246
Government subsidies			12,238				4,712				–				–				16,950
Foreign exchange gain (loss), net			(9,647	)			4,292,067				6,215				4,998				4,293,633
Net gain from related parties debt restructuring			–				–				–				1,460,543				1,460,543
Professional fees on acquisition of HTL Marketing			–				(133,960	)			–				(1,127,600	)			(1,261,560	)
Scrap sofa sale income			–				223,263				–				–				223,263
Sundry income (expense)			78,284				21,551				7				(60,438	)			39,404
Change in fair value of derivatives financial instruments			–				(753,243	)			–				–				(753,243	)
Total other income (expenses), net			(44,178	)			3,275,913				(204,374	)			277,503				3,304,864
Income (loss) before income taxes			(1,375,056	)			14,024,163				108,788				(404,548	)			12,353,347
Income tax expense			–				(2,310,779	)			(18,493	)			–				(2,329,272	)
Segment income (loss)		$	(1,375,056	)		$	11,713,384			$	90,295			$	(404,548	)		$	10,024,075

		Six months ended June 30, 2026
		Retail Sales				Export Sales				Leather Trading				Corporate and unallocated				Total
Revenues, net
From third party		$	5,313,821			$	185,418,405			$	–			$	–			$	190,732,226
From related parties			–				874,947				6,697,933				–				7,572,880
			5,313,821				186,293,352				6,697,933				–				198,305,106
Cost of goods sold			(1,876,931	)			(133,106,987	)			(6,327,510	)			–				(141,311,428	)
Gross profit			3,436,890				53,186,365				370,423				–				56,993,678
Operating expenses:
Sales and distribution expenses			(3,385,506	)			(33,560,786	)			(21,130	)			–				(36,967,422	)
General and administrative expenses			(694,444	)			(8,432,743	)			(1,969	)			(1,198,702	)			(10,327,858	)
Total operating expenses			(4,079,950	)			(41,993,529	)			(23,099	)			(1,198,702	)			(47,295,280	)
Operating income (loss)			(643,060	)			11,192,836				347,324				(1,198,702	)			9,698,398
Other income (expenses):
Interest expense			–				(40,734	)			(109,881	)			–				(150,615	)
Interest income			465				18,421				307				–				19,193
Government subsidies			15,685				7,700				–				–				23,385
Foreign exchange gain (loss), net			(2,426	)			(2,319,989	)			163,712				(9,654	)			(2,168,357	)
Scrap sofa sale income			–				165,621				–				–				165,621
Change in fair value of derivatives financial instruments			–				74,765				–				–				74,765
Sundry income (expense)			89,747				(208,528	)			–				266,876				148,095
Total other income (expenses), net			103,471				(2,302,744	)			54,138				257,222				(1,887,913	)
Income (loss) before income taxes			(539,589	)			8,890,092				401,462				(941,480	)			7,810,485
Income tax expense			–				(1,674,699	)			(68,248	)			–				(1,742,947	)
Segment income (loss)		$	(539,589	)		$	7,215,393			$	333,214			$	(941,480	)		$	6,067,538

HOMESTOLIFE LTD AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Currency expressed in United States Dollars (“US$”), except for number of shares)
		Six months ended June 30,
		2025			2026
		USD			USD
Net cash used in operating activities		(11,241,457	)		(8,266,135	)
Net cash used in investing activities		(557,755	)		(1,951,009	)
Net cash provided by financing activities		5,966,454			1,457,160
Effect on exchange rate change on cash and cash equivalents, and restricted cash		1,043,524			(299,544	)
Net change in cash and cash equivalents, and restricted cash		(4,789,234	)		(9,059,528	)
BEGINNING OF PERIOD		24,860,621			27,276,091
END OF PERIOD		20,071,387			18,216,563

HONG KONG, Sept. 30, 2026 (GLOBE NEWSWIRE) — DarkIris Inc. (Nasdaq: DKI) (the “Company” or “DarkIris”), an innovative technology provider in the digital media and entertainment sector, today provided a business update highlighting recent progress in the development and global deployment of its flagship AI video production platform, Cine3.AI, as well as the Company’s North American expansion and interactive entertainment initiatives.

Advancing Cine3.AI for the “Cinema 3.0” Era

Following continued system development and optimization of its multimodal production workflows, DarkIris is advancing preparations for the global rollout of Cine3.AI, its professional AI-powered film production platform. The platform is currently undergoing pre-launch compliance review, testing and operational preparations ahead of its planned international launch.

DarkIris believes the global film and entertainment industry is entering what the Company refers to as the “Cinema 3.0” era, characterized by the increasing integration of generative AI technologies into professional content production workflows.

Cine3.AI integrates capabilities including high-fidelity visual generation, character consistency management and dynamic motion generation. The platform is designed for professional filmmakers, multi-channel network (“MCN”) operators and content production teams, providing tools that support multiple stages of the production process, including pre-visualization, shot rendering and post-production assistance.

Building on the Cine3.AI platform, DarkIris also intends to expand its participation across the film production value chain through AI-assisted production, co-production, and technology services for film, advertising, and other content projects.

Establishment of U.S. Subsidiary to Support North American Expansion

To further expand its presence in key entertainment markets and pursue growing commercial opportunities, DarkIris has established DarkIris US Inc., a wholly owned subsidiary in the United States.

The subsidiary is expected to serve as the Company’s operating hub in North America, with an initial focus on:

• supporting the global commercialization of Cine3.AI and engagement with enterprise customers;
• pursuing opportunities involving the acquisition and licensing of film and digital intellectual property (“IP”); and
• providing AI-enabled production, co-production, and technology services for film, advertising, and other content projects in North America and international markets.

The U.S. subsidiary is expected to play a key role in DarkIris’ broader strategy to develop localized commercial capabilities in key entertainment markets worldwide.

Global Talent Initiative Reinforcing the Dual-Hub Model of Singapore and U.S. Operations

To support the commercialization of Cine3.AI and the Company’s international expansion, DarkIris has also initiated a global talent recruitment program centered on its strategic operations in Singapore and the United States.

The initial recruitment initiative will focus on senior positions in corporate administration, business development, IP operations and cross-border compliance. Through the development of localized business and operating teams, the Company intends to strengthen its engagement with film studios, advertising companies and digital entertainment participants across North America and the Asia-Pacific region.

Expanding into Interactive Entertainment Through “Quantum Project X”

In addition to its AI-powered film production technology, DarkIris is extending its digital entertainment ecosystem into interactive entertainment.

The Company is developing “Quantum Project X,” a historical strategy game.

Leveraging DarkIris’ internally developed AI visual production pipeline, Quantum Project X represents an extension of the Company’s core AI technology assets into interactive entertainment. The project is designed to explore opportunities to develop and commercialize IPs across both film and gaming formats.

DarkIris currently expects to complete development of Quantum Project X for open beta testing (“OBT”) and commence testing in Q2 2027. The timeline remains subject to the development process, testing results and other operational considerations.

Management Commentary

Mr. Zhifang Hong, Chief Executive Officer and Chairman of DarkIris, commented: “As we continue to build the technology foundation for ‘Cinema 3.0’ era, DarkIris is entering a new stage of development. By combining the core capabilities of Cine3.AI with localized production and commercial capabilities in North America, supported by our talent strategy across Singapore and the United States, we believe we are well positioned to pursue emerging opportunities across media and digital entertainment.”

Business Inquiries & Partnerships

To support the continued development of its global commercial ecosystem, DarkIris has established dedicated channels for the following areas of business cooperation:

Film Production & VFX Services
Email: production@cine3.ai

Cine3.AI Platform & Enterprise Partnerships
Cine3.AI Platform Website: https://cine3.ai/assets
Email: partner@cine3.ai

IP Licensing & Rights Acquisition
Email: partners@darkiris.com

Gaming & Interactive Co-Publishing
Email: bd@darkiris.com

About DarkIris Inc.

DarkIris Inc. (Nasdaq: DKI) is an innovative, growth-oriented public company focused on AI-driven digital media and content production technologies. Through advanced production capabilities, including its artificial intelligence platform, aideptus.com, the Company aims to provide creators, studios, and developers with generative AI solutions designed to streamline creative workflows and enhance digital content production experiences. For more information, please visit the Company’s website at www.darkiris.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions, the Company’s ability to comply with Nasdaq continued listing standards and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

DarkIris Inc.
Investor Relations Department
Email: dki@darkiris.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1 646-932-7242
Email: investors@ascent-ir.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4761dc83-7589-4e91-9a59-d331a0604ab2

https://www.globenewswire.com/NewsRoom/AttachmentNg/f81d6e3b-1a50-4476-8f20-e5a2c0017dd8

https://www.globenewswire.com/NewsRoom/AttachmentNg/ddb66c2c-04c2-4fa3-b4dc-6eba926dd449